1. Scarpa A, Capelli P, Zamboni G, Oda T, Mukai K, Bonetti F, Martignoni G,
Iacono C, Serio G, Hirohashi S. Neoplasia of the ampulla of Vater. Ki-ras
and p53 mutations. Am J Pathol. 1993;142:1163–72.
2. Kaiser A, Jurowich C, Schonekas H, Gebhardt C, Wunsch PH. The adenoma-carcinoma sequence applies to epithelial tumours of the papilla of
Vater. Z Gastroenterol. 2002;40:913–20.
3. Yoon YS, Kim SW, Park SJ, Lee HS, Jang JY, Choi MG, Kim WH, Lee KU, Park
YH. Clinicopathologic analysis of early ampullary cancers with a focus on
the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.
4. Roggin KK, Yeh JJ, Ferrone CR, Riedel E, Gerdes H, Klimstra DS, Jaques DP,
Brennan MF. Limitations of ampullectomy in the treatment of nonfamilial
ampullary neoplasms. Ann Surg Oncol. 2005;12:971–80.
5. Yamamoto K, Itoi T, Sofuni A, Tsuchiya T, Tanaka R, Tonozuka R, Honjo
M, Mukai S, Fujita M, Asai Y, Matsunami Y, Kurosawa T, Yamaguchi H,
Nagakawa Y. Expanding the indication of endoscopic papillectomy for
T1a ampullary carcinoma. Dig Endosc. 2019;31:188–96.
6. Yoon SM, Kim MH, Kim MJ, Jang SJ, Lee TY, Kwon S, Oh HC, Lee SS, Seo
DW, Lee SK. Focal early stage cancer in ampullary adenoma: surgery or
endoscopic papillectomy? Gastrointest Endosc. 2007;66:701–7.
7. Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota
T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K,
Tanaka et al. BMC Gastroenterol
8. 9. 10. 11. 12. 13. 14. 15. 16. (2021) 21:224
Nagino M, Hirano S, Wakai T, Wada K, Isayama H, Okusaka T, Tsuyuguchi T,
Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma
Y, Yoshida M, Takayashiki T, Takada T. Clinical practice guidelines for the
management of biliary tract cancers 2015: the 2nd English edition. J
Hepatobiliary Pancreat Sci. 2015;22:249–73.
Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H,
Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical
practice guidelines for the management of biliary tract cancers 2019: the
3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28:26–54.
Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J, Takasawa O, Obana T.
Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled
study. Gastrointest Endosc. 2007;66:740–7.
Ito K, Fujita N, Noda Y. Endoscopic diagnosis and treatment of ampullary
neoplasm (with video). Dig Endosc. 2011;23:113–7.
Daikuhara S, Uehara T, Higuchi K, Hosaka N, Iwaya M, Maruyama Y,
Matsuda K, Arakura N, Tanaka E, Ota H. Insulin-like growth factor II mRNAbinding protein 3 (IMP3) as a useful immunohistochemical marker for
the diagnosis of adenocarcinoma of small intestine. Acta Histochem
Cytochem. 2015;48:193–204.
Plum PS, Ulase D, Bollschweiler E, Chon SH, Berlth F, Zander T, Alakus H,
Hölscher AH, Bruns CJ, Schallenberg S, Quaas A, Loeser H. Upregulation
of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the
esophagus. J Cancer Res Clin Oncol. 2018;144:1731–9.
Xu W, Sheng Y, Guo Y, Huang Z, Huang Y, Wen D, Liu CY, Cui L, Yang Y, Du
P. Increased IGF2BP3 expression promotes the aggressive phenotypes of
colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019;234:18466–79.
Tschirdewahn S, Panic A, Püllen L, Harke NN, Hadaschik B, Riesz P, Horváth
A, Szalontai J, Nyirády P, Baba HA, Reis H, Szarvas T. Circulating and tissue
IMP3 levels are correlated with poor survival in renal cell carcinoma. Int J
Cancer. 2019;145:531–9.
Okabayshi M, Kataoka TR, Oji M, Mibayashi S, Odani K, Otsuka A, Haga H.
IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions. Diagn Pathol. 2020;15:26.
Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Oxford: Wiley; 2017.
Page 10 of 10
17. Kawashima H, Ohno E, Ishikawa T, Iida T, Tanaka H, Furukawa K, Nakamura
M, Honda T, Hashimoto S, Ito A, Ishigami M, Hirooka Y, Fujishiro M.
Endoscopic papillectomy for ampullary adenoma and early adenocarcinoma: analysis of factors related to treatment outcome and long-term
prognosis. Dig Endosc. 2020. https://doi.org/10.1111/den.13881.
18. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von HippelLindau gene product, and IMP3 serve as a useful immunohistochemical
panel in the diagnosis of adenocarcinoma on endoscopic bile duct
biopsy. Hum Pathol. 2010;41:1210–9.
19. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is
a novel progression marker in malignant melanoma. Mod Pathol.
2008;21:431–7.
20. Kawabata Y, Tanaka T, Nishisaka T, Inao T, Nishi T, Yano S. Cytokeratin 20
(CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: correlation with tumor progression and prognosis. Diagn Pathol. 2010;5:75.
21. Trikudanathan G, Njei B, Attam R, Arain M, Shaukat A. Staging accuracy of
ampullary tumors by endoscopic ultrasound: meta-analysis and systematic review. Dig Endosc. 2014;26:617–26.
22. Itoh A, Goto H, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. Intraductal
ultrasonography in diagnosing tumor extension of cancer of the papilla
of Vater. Gastrointest Endosc. 1997;45:251–60.
23. Menzel J, Hoepffner N, Sulkowski U, Reimer P, Heinecke A, Poremba C,
Domschke W. Polypoid tumors of the major duodenal papilla: preoperative staging with intraductal US, EUS, and CT—a prospective, histopathologically controlled study. Gastrointest Endosc. 1999;49:349–57.
24. Liu H, Shi J, Anandan V, Wang HL, Diehl D, Blansfield J, Gerhard G, Lin F.
Reevaluation and identification of the best immunohistochemical panel
(pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Arch Pathol Lab Med. 2012;136:601–9.
25. Kawashima H, Itoh A, Ohno E, Miyahara R, Ohmiya N, Tanaka T, Shimoyama Y, Nakamura S, Ebata T, Nagino M, Goto H, Hirooka Y. Diagnostic and
prognostic value of immunohistochemical expression of S100P and IMP3
in transpapillary biliary forceps biopsy samples of extrahepatic bile duct
carcinoma. J Hepatobiliary Pancreat Sci. 2013;20:441–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
...